Abstract
PSY22 - Patient-Reported Outcome Claims in European and United States Orphan Drug Approvals
Highlights
PSY19 INFORMING THE DESIGN OF WEIGHT LOSS PROGRAMS USING A DISCRETE CHOICE EXPERIMENT Church J1, Goodall S2, Mulhern B3, van Gool K2, Haas M4 1University of Technology, Haymarket, Australia, 2University of Technology, Sydney, Sydney, Australia, 3University of Technology Sydney, Sydney, Australia, 4University of Technology Sydney, Haymarket, Australia OBJECTIVES: Given rising obesity rates, decision makers need inputs that can help in the prioritisation of funding for obesity interventions
The strongest preference for all weight groups was improvements in quality-of-life. These findings provide insights into why some people fail and others succeed when adopting a lifestyle intervention, which can aid in policy development for the design of weight loss interventions
Orphan drug approval documentation was obtained from the European Medicines Agency (EMA) website
Summary
PSY19 INFORMING THE DESIGN OF WEIGHT LOSS PROGRAMS USING A DISCRETE CHOICE EXPERIMENT Church J1, Goodall S2, Mulhern B3, van Gool K2, Haas M4 1University of Technology, Haymarket, Australia, 2University of Technology, Sydney, Sydney, Australia, 3University of Technology Sydney, Sydney, Australia, 4University of Technology Sydney, Haymarket, Australia OBJECTIVES: Given rising obesity rates, decision makers need inputs that can help in the prioritisation of funding for obesity interventions. RESULTS: Compared remifentanil with fentanyl, 13.98RMB is needed to reduce 1 minute emergency time in thoracoabdominal surgery(23 RCTs involving 1280 patients). 9.45RMB is needed to reduce 1 minute of emergency time in interventional minimally invasive surgery(47 RCTs involving 4691 patients).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
